Cholesterol, statins and dementia.
OBJECTIVE
Advances in cholesterol biology suggest that cholesterol metabolism modulates beta-amyloid production, and that pharmaceuticals that inhibit cholesterol metabolism might be valuable in therapy of Alzheimer's disease. Although the genetics and cell biology continue to support the link between cholesterol and Alzheimer's disease, recent clinical studies suggest that the animal studies might not directly translate to clinical studies in humans.


RESULTS
This review will highlight advances in genetics, cell biology and clinical sciences investigating the relationship between cholesterol and Alzheimer's disease.


CONCLUSIONS
Cholesterol, its catabolites and proteins that regulate cholesterol levels all modulate processing of amyloid precursor protein. Statins hold promise in therapy of Alzheimer's disease, but the current data are more consistent with a model of statins that act as neuroprotective agents rather than inhibitors of beta-amyloid production.
Wolozin
Benjamin
B
Department of Pharmacology, Boston University School of Medicine, L-603, Boston, MA 02118-2526, USA. bwolozin@bu.edu
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000209:etiology* / Q000235:genetics; D016564:Amyloid beta-Protein Precursor / Q000187:drug effects / Q000235:genetics; D002784:Cholesterol / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors
D016564:Amyloid beta-Protein Precursor; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol